Video Library
The Emerging Role of Inclisiran in Atherosclerotic Cardiovascular Disease Management
Welcome to our latest video! This video explores the emerging role of inclisiran, a small interfering RNA (siRNA) therapeutic that targets PCSK9, in the management of atherosclerotic cardiovascular disease. The summary delves into the mechanism of actions of inclisiran, its safety profile, results from clinical trials and the latest data presented at the ESC congress.
First published: January 13, 2025
Running time: 58 minutes, 46 seconds
01.28 Concept of cumulated LDL exposure (mg-years)
05.11 Re-defining secondary prevention
08.04 Early secondary prevention
11.27 Late secondary prevention (CHD)
19.17 Late secondary prevention (PAD)
20.15 Very late secondary prevention (ACS)
23.18 Longer is better
24.55 Earlier is better
26.21 Younger is better
28.39 Older Adults also deserve treatment
41.12 Audience Q&A
Video Library
“Lower, Longer, Sooner, Earlier, and Younger”: Do we have enough evidence?
Prof. Chiang discusses Atherosclerotic Cardiovascular Disease (ASCVD) in context of cumulated LDL exposure, and the different stages of secondary prevention and how starting to manage the disease at a younger age or earlier stage is beneficial. At 41:12 he answers audience questions.
First published: October 25, 2023
Running time: 35 minutes, 49 seconds
00.00 Patients and plaque
03.30 Pictorial representation and
primary prevention or adherence07.00 Calcium Scoring
13.00 Other targets: Lp(a)
21.00 Triglycerides
28.00 Special: Latest data from ESC
Video Library
ASCVD Roundtable Part 2: Other targets and ESC 2023 Highlights
In this second part of the Round Table conversation, the Editorial Panel discuss how showing patients’ images of their plaques help with adherence, discuss other targets such as Lp (a) and triglycerides and most importantly, discuss some of the latest data from the recently concluded ESC congress.
Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt
First published: September 1, 2023
Running time: 25 minutes, 25 seconds
00.00 Introduction
01.21 LDL target and guidelines
07.55 Should we start combination
therapy early?12.35 Side effects of combination
therapy?16.40 Dosing in combination
therapy – InclisiranVideo Library
ASCVD Roundtable Part 1: Target guidelines, dosing, and compliance in lipid lowering therapies
In recognition of the ASCVD & Lipidology Knowledge Hub 2 year anniversary, the esteemed faculty members for this educational resource site met to discuss the hot topics that have occurred over this time. Come and take a seat at this roundtable discussion with Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, and Prof. Deepak Bhatt as they discuss target guidelines, dosing, and compliance in lipid lowering therapies.
Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt
First published: August 1, 2023
Video Library
The SANTORINI Study: Why Are Lipid Control Therapies Not Working?
In this video, we summarize the results from the SANTORINI trial which documents the effectiveness of current treatment practice in managing LDL-C levels for patients in the higher CV risk categories in and how care may be improved.
First published: July 12, 2023